[1]Zhao Y, Xu S, Wang L, et al. National survey of drug-resis-tant tuberculosis in China. N Engl J Med,2012,366(23):2161-2170.[2]World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11. Geneva: World Health Organization, 2013.[3]刘志辉,罗一鲁. 结核病实验诊断现状及展望.中国防痨杂志,2003,25(1):38-40.[4]宋凯.咳痰时间、痰标本性状与涂片抗酸杆菌检出关系分析.中国防痨杂志,2008,30(5):414-416.[5]王巍,李洪敏,王安生,等.BACTEC-MGIT 960 快速培养药敏对肺结核诊治的应用和评价.中国防痨杂志,2003,25(6):379-381.[6]张娟,蒋俊,张红,等. MGIT 960与罗氏培养法在结核分枝杆菌培养及药敏试验中的比对分析.中国防痨杂志,2011,33(6):361-365.[7]李丽莉,杨蕾,陈保文,等.我国结核病血清学检测试剂调查结果简析.中国防痨杂志,2012,34(11):740-742.[8]World Health Organization. Commercial serodiagnostic tests for diagnosis of tuberculosis policy statement. WHO/HTM/TB/2011.5. Geneva: World Health Organization, 2011.[9]Mazurek GH, Jereb J, Vernon A,et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep,2010,59(RR-5):1-25.[10]中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告(2011年)(第一部分结核病临床诊断). 中国防痨杂志,2012,34(6):393-403.[11]中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告(2012年)(第一部分结核病临床诊断). 中国防痨杂志,2013,35(6):405-426.[12]李红,唐神结,史祥,等.全血γ-干扰素释放试验对涂阴肺结核诊断价值的研究. 中华临床医师杂志(电子版),2012,6(16):4894-4897.[13]World Health Organization. Rapid implementation of the Xpert Mtb/RIF diagnostic test. WHO/HTM/TB/2011.2. Geneva: World Health Organization,2011.[14]World Health Organization. The use of molecular line probe assay for the detection of resistant to second-line anti-tuberculosis drugs. WHO/HTM/TB/2013.01. Geneva: World Health Organization,2013.[15]Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med,2010,363(11):1005-1015.[16]胡忠义.结核分枝杆菌耐药性快速测定方法及其评价.中华结核和呼吸杂志,2003,26(2):107-109.[17]菅记涌,王嫩寒,易俊莉,等. MTBDR plus方法快速检测北京地区临床结核分枝杆菌分离株利福平和异烟肼耐药性效果评价.中国防痨杂志,2010,32(10):611-614.[18]陈殿森,关文华,张璇.低剂量CT扫描在评价老年菌阴性肺结核患者抗结核治疗效果中的应用.中华老年医学杂志,2011,30(8):626-628.[19]杨静,马大庆,张岩松,等. 急性粟粒性肺结核的CT及病理对照研究.中华放射学杂志,2011,45(6):520-523.[20]唐神结,高文. 临床结核病学. 北京:人民卫生出版社,2011:191-200.[21]唐神结. 耐药结核病防治手册. 北京:人民卫生出版社,2009:72-74.[22]中国防痨协会. 耐药结核病化学治疗指南(2009). 中国防痨杂志,2010, 32(4):181-198.[23]Tang S, Zhang Q, Yu J, et al. Extensively drug-resistant tuberculosis, China. Emerg Infect Dis, 2011,17(3):558-560.[24]中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告(2011年)(第二部分结核病临床治疗). 中国防痨杂志,2012,34(7):463-471.[25]中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告(2012年)(第二部分结核病临床治疗).中国防痨杂志,2013,35(7):488-510.[26]Tang SJ, Zhang Q, Zeng LH, et al. Efficacy and safety of line-zolid in the treatment of extensively drug-resistant tuberculosis. Jpn J Infect Dis, 2011,64(6):509-512.[27]Zhang L, Pang Y, Yu X,et al. Linezolid in the treatment of extensively drug-resistant tuberculosis.Infection,2014,42(4):705-711.[28]傅瑜.重视支气管结核的综合及介入治疗.中华结核和呼吸杂志,2011,34(5):325-326.[29]中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 气管支气管结核诊断和治疗指南(试行). 中华结核和呼吸杂志,2012,35(8):581-587.[30]唐神结. 结核病临床诊治进展年度报告(2013年). 北京:人民卫生出版社,2014.[31]Kurbatova EV, Kaminski DA, Erokhin VV,et al. Perfor-mance of Cepheid Xpert MTB/RIF and TB-Biochip MDR in two regions of Russia with a high prevalence of drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis, 2013, 32(6):735-743.[32]Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis, 2014,14(4):327-340.[33]唐神结,刘一典,张占军,等.选择耐多药结核病化疗方案的若干问题.中国防痨杂志,2014,36(7):521-524.[34]Butov DA, Efremenko YV, Prihoda ND, et al. Adjunct immune therapy for first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunotherapy, 2012, 4(7):687-695.[35]Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled Phase Ⅰ Clinical Trial of the therapeutical antituberculous vaccine RUTI.Vaccine, 2010, 28(4): 1106-1116.[36]Ahn SS, Jeon BY, Park SJ, et al. Nonlytic Fc-fused IL-7 syner-gizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis. Vaccine, 2013, 31(27):2884-2890.[37]Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med, 2011,84(4):361-369.[38]Feng G, Jiang Q, Xia M, et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS One, 2013, 8(4):e61135. |